Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A systematic review of 10 trials with qualitative synthesis only, reporting descriptive findings about survival disparities without meta-analytic effect sizes, confidence intervals, or quantified comparisons between HER2-low and HER2-positive cohorts.
Real-world observational study confirming efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer, consistent with historical trial data but limited by small single-centre sample and descriptive design.
A narrative review synthesizing randomized trial evidence and recent regulatory approvals to propose a risk-adapted treatment framework for HER2-positive early-stage breast cancer, not reporting original trial data.
Real-world retrospective pharmacy data on persistence and adherence without clinical outcomes, efficacy comparison, or prospective validation; describes treatment patterns rather than clinical benefit or harm.
First-in-vivo evidence from a single small animal study without clinical validation, demonstrating mechanism but requiring confirmation in larger preclinical and human studies before clinical application.
Retrospective single-center study of 87 patients identifying progression patterns as prognostic factors for post-progression survival in CDK4/6-inhibitor-treated HR+/HER2− metastatic breast cancer, with statistically significant hazard ratios for visceral and liver progression but limited by design and sample size.
Real-world observational study reporting descriptive testing patterns and mutation prevalence without a comparator or causal inference; provides practice-relevant epidemiology but limited mechanistic or interventional evidence.
Retrospective single-center cohort confirming that CDK4/6 inhibitors with endocrine therapy produce PFS and OS outcomes consistent with pivotal trials in HR+/HER2− metastatic breast cancer, but lacks the design rigor and sample size for practice guidance beyond established use.